bioscience schreef op 7 maart 2014 08:57:
Kijk dat is weer eens mooi nieuws .Goed gevonden Cruson
“These results again confirm the prognostic value of our PredictMDx test in glioblastoma. These results demonstrate the clinical importance of using molecular biomarkers, like MGMT, to improve patient stratification and the current standard of care,” Dr. Wim van Criekinge, MDxHealth’s chief scientific officer, said in the statement.